Efficacy and Safety of HSK3486 Compared to Propofol in Induction of General Anesthesia in Adults Having Elective Surgery
A Multicenter, Randomized, Double-blinded, Propofol-controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion for Induction of General Anesthesia in Adults Undergoing Elective Surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85053
- Arizona Research Center
-
-
California
-
Pasadena, California, United States, 91105
- Lotus Clinical Research, LLC
-
-
Florida
-
Tamarac, Florida, United States, 33321
- Phoenix Clinical Research, LLC
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- The University of Chicago Medicine
-
-
New York
-
New York, New York, United States, 10013
- New York City Heath and Hospitals
-
Stony Brook, New York, United States, 11794
- Stony Brook University Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- UNC Health Care System
-
Durham, North Carolina, United States, 27705
- Duke University
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Research Foundation
-
-
Texas
-
Bellaire, Texas, United States, 77401
- HD Research
-
Plano, Texas, United States, 75093
- Plano Surgical Hospital
-
San Antonio, Texas, United States, 78229
- Endeavor Clinical Trials, LLC
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- JBR Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects undergoing elective surgery (nonemergency, noncardiothoracic, and nonintracranial surgery anticipated to last at least 1 hour ).
- Males or females, aged ≥18 years old, with American Society of Anesthesiologists Physical Status (ASA PS) I to IV.
- Body mass index (BMI) ≥18 kg/m2.
- For all females of childbearing potential, negative pregnancy test at screening and baseline. Additionally, females of childbearing potential must agree to use birth control (such as condom, intrauterine device [IUD], abstinence) from the time of consent until 30 days post study drug administration.
- Capable of understanding the procedures and methods of this study, willing to sign an Informed Consent Form, and to complete this study in strict compliance with the study protocol.
Exclusion Criteria:
- Contraindications to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.
- Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subject having contraindications to propofol, opioids, and their antidotes.
- Medical condition or evidence of increased sedation/general anesthesia risk.
- Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study.
- Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics.
- Laboratory parameters significantly out of range at screening.
- Female subjects with a positive pregnancy test (serum or urine) at screening or baseline; lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
- Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HSK3486
HSK3486 for induction of general anesthesia.
|
HSK3486 for induction of general anesthesia.
|
|
Active Comparator: Propofol
Propofol for induction of general anesthesia.
|
Propofol for induction of general anesthesia.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Successful Anesthesia Induction
Time Frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
|
The primary outcome of interest was the success rate of anesthesia induction, defined by the proportion of subjects with successful anesthesia.
A subject was considered successful for anesthetic induction if the following conditions were met: induction success Modified Observer's Assessment of Awareness/Sedation Scale (MOAA/S ≤1) after administration of study drug and 1 or less top-up dose required without using any rescue drugs.
Where Grade 0 is no response after trapezius squeeze, Grade 1 responds only after painful trapezius squeeze and Grade 5 is completely awake responds to name spoken in normal tone.
|
From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression.
Time Frame: 15 minutes from end of drug administration.
|
The proportion of subjects with successful induction who maintain the desired depth of anesthesia for general elective surgery, AND without significant cardiac and respiratory depression between the time of successful induction and 15 minutes post initiation of study drug administration, or up to the beginning of second tracheal intubation attempt if it is a difficult condition and not beyond 15 minutes post initiation of study drug administration.
|
15 minutes from end of drug administration.
|
|
Proportion of Subjects With Any Injection-site Pain on Numeric Rating Scale.
Time Frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
|
The proportion of subjects with any injection-site pain at time of drug administration on the Numeric Rating Scale (NRS ≥1).
|
From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
|
|
Subjects' NRS Pain Score
Time Frame: Up to 8 hours
|
Injection-site pain is evaluated verbally during study drug administration using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worse imaginable pain).
Subjects' NRS pain score at the time of study drug administration (Day 1) and recall of pain score in PACU.
|
Up to 8 hours
|
|
Time to Successful Induction of General Anesthesia.
Time Frame: From end of drug administration to MOAA/S ≤1 (up to 5 minutes)
|
Time from the end of the first administration of the study drug to MOAA/S ≤1.
|
From end of drug administration to MOAA/S ≤1 (up to 5 minutes)
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants That Failed to Meet Successful Induction of General Anesthesia
Time Frame: From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
|
Failed to meet successful induction of general anesthesia defined by the use of the Top-up Study Drug and Rescue/Remediation Drugs
|
From start of drug administration to MOAA/S ≤1 (up to 5 minutes)
|
|
Time to the Disappearance of Eyelash Reflex
Time Frame: From end of drug administration to disappearance of eyelash reflex (up to 5 minutes)
|
Time from the end of the first administration of the study drug to the disappearance of eyelash reflex.
|
From end of drug administration to disappearance of eyelash reflex (up to 5 minutes)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: William Daley, MD, Haisco-USA Pharmaceuticals, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HSK3486-304
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.